© Foto: ZUMAPRESS.com | Andre M. Chang - picture alliance
© 2024 wallstreetONLINE
Realtime | Geld | Brief | Zeit |
---|---|---|---|
149,12 | 149,24 | 13:57 | |
149,12 | 149,36 | 13:58 |
© Foto: ZUMAPRESS.com | Andre M. Chang - picture alliance
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
09:54 | Johnson & Johnson Reports Promising Interim Data From Phase 2 SunRISe-4 Study | NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) Monday announced positive interim data from the Phase 2 SunRISe-4 study of TAR-200 in combination with cetrelimab in patients suffering from... ► Artikel lesen | |
08:50 | Johnson & Johnson: Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer | TAR-200 plus cetrelimab effective in reducing tumor size in those with muscle-invasive disease, potentially improving surgical outcomes and lowering risk of recurrence
BARCELONA, Spain, Sept. 16... ► Artikel lesen | |
So | J&J's TAR-200 Phase 2b SunRISe-1 Study Shows 84% Complete Response In High-Risk Bladder Cancer | NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) announced additional results from the pivotal Phase 2b SunRISe-1 study, supporting the safety and efficacy profile of investigational TAR-200... ► Artikel lesen | |
So | Johnson & Johnson: New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer | Investigational TAR-200 monotherapy demonstrates high complete response rate without the need for reinduction or additive therapy in patients who are Bacillus Calmette-Guérin (BCG)-unresponsive
... ► Artikel lesen | |
Sa | J&J leads H1 healthcare deals as Big Pharma dealmaking returns: report |